Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC)

148 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2018.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 118 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 34,209,499 shares of 104,661,494 outstanding shares and own 32.69% of the company stock.
Largest 10 shareholders include Essex Woodlands Management, Inc. (3,842,047 shares), WELLINGTON MANAGEMENT GROUP LLP (3,814,034 shares), JPMORGAN CHASE & CO (3,437,417 shares), FRANKLIN RESOURCES INC (3,173,162 shares), BlackRock Inc. (2,410,444 shares), Bank of New York Mellon Corp (2,013,231 shares), ArrowMark Colorado Holdings LLC (1,735,699 shares), NovaQuest Capital Management, L.L.C. (1,558,426 shares), MILLENNIUM MANAGEMENT LLC (1,494,441 shares), and JENNISON ASSOCIATES LLC (1,483,037 shares).
This table shows the top 118 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.